Findings

What do systematic reviews say?

821 questions · 842 findings · 96 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 275 · 32.7%GRADE not reported 88 · 10.5%Very low 197 · 23.4%Low 187 · 22.2%Moderate 86 · 10.2%High 9 · 1.1%

Nebulized budesonide vs viscous budesonide

Histological improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Nebulized budesonide vs viscous budesonide

Endoscopic improvement (dichotomous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Corticosteroids vs placebo

Clinical improvement (continuous) · inactive EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 269 participants
Very low

Nebulized budesonide vs viscous budesonide

Endoscopic improvement (continuous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulized budesonide vs viscous budesonide

Withdrawals due to adverse events · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Viaskin milk patch vs placebo

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Fecal microbiota transplantation vs control

Induction of clinical remission in UC at longest · people with active UC

Fecal microbiota transplantation may leads to higher induction of clinical remission in UC at longest compared with control (low certainty).

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
RR 1.79 [1.13, 2.84]
10 studies · 468 participants
Low

Fecal microbiota transplantation vs control

Induction of clinical remission in CD · Patients with active Crohn's disease

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Fecal microbiota transplantation vs control

Serious adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Fecal microbiota transplantation vs control

Any adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Fecal microbiota transplantation vs control

Induction of endoscopic remission in CD · Patients with active Crohn's disease

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Fecal microbiota transplantation vs control

Quality‐of‐life scores with use of FMT for induction of remission in CD · Patients with active Crohn's disease

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Fecal microbiota transplantation vs control

Serious adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC

It is very uncertain whether fecal microbiota transplantation changes serious adverse events with use of FMT for induction of remission in… compared with control (very low certainty).

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
RR 1.77 [0.88, 3.55]
10 studies · 468 participants
Very low